Who is sponsoring NCT00388674?

NCT00388674 is sponsored by Bristol-Myers Squibb.

What condition does NCT00388674 study?

NCT00388674 studies Chronic Hepatitis B.

What drugs are being tested in NCT00388674?

Interventions: entecavir, Other anti-HBV medication.

What is the status of NCT00388674?

NCT00388674 is currently COMPLETED.

Last reviewed 2018-07-30 · How we verify

Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

NCT00388674 COMPLETED Results posted

The purpose of this study is to prospectively assess the long-term outcomes (benefits and risks) associated with entecavir (ETV) therapy as compared to other antivirals approved for the treatment of chronic HBV infection. For the China substudy, patients randomized to entecavir will have safety and efficacy assessments performed during the first year of the study.

Details

Lead sponsor	Bristol-Myers Squibb
Status	COMPLETED
Enrolment	12522
Start date	Mon Dec 18 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Chronic Hepatitis B

Interventions

entecavir
Other anti-HBV medication

Countries

Italy, Colombia, Taiwan, Poland, South Korea, Philippines, Russia, Mexico, Thailand, Czechia, Portugal, United States, France, Greece, Argentina, Canada, Romania, Brazil, Spain, Germany, China, Singapore, Turkey (Türkiye), India